To ask the Secretary of State for Business, Energy and Industrial Strategy, with reference to his Department's policy paper entitled Life Science Vision, published on 6 July 2021, what discussions he has had with representatives of the domestic medical cannabis sector on the speed of uptake of proven products and potential barriers to the spread of new technologies.

We developed the Life Sciences Vision with wide engagement across the sector, including those involved with a wide range of therapeutic modalities. As part of this we considered carefully matters of regulation, access and uptake of new products – but not specifically with medicinal cannabis producers. We were careful to consider wider work on this issue, including the Taskforce on Innovation, Growth and Regulatory Reform report.